Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions

Lignende værker

• CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
  af: Spring, Laura M., et al.
  Udgivet: (2019)
• Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
  af: Spring, Laura M., et al.
  Udgivet: (2017)
• Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase.
  af: Kato, J Y, et al.
  Udgivet: (1994)
• Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation
  af: Bockstaele, Laurence, et al.
  Udgivet: (2009)
• EXTH-36. PHARMACEUTICAL INHIBITION OF CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) IN GLIOBLASTOMA
  af: Nuga, Oluwademilade, et al.
  Udgivet: (2020)